Vaccination against respiratory Pseudomonas aeruginosa infection

References

• Kidd T, Whiley D, Bell S, Grimwood K. Pseudomonas. In: Liu D, ed. Molecular detection of human bacterial pathogens. Boca Raton, FL.: CRC Press, 2011:1009-21.
   Google Scholar
• KlockgetherJ, CramerN, WiehlmannL, DavenportCF, TümmlerB. Pseudomonas aeruginosa Genomic Structure and Diversity. Front Microbiol2011; 2:150; http://dx.doi.org/10.3389/fmicb.2011.00150; PMID: 21808635
   PubMed Web of Science ®Google Scholar
• Pier G, Ramphal R. Pseudomonas aeruginosa. In: Mandell G, Bennett J, Dolin R, eds. Mandell, Douglas and Bennett’s principles and practice of infectious diseases. Philadelphia: Churchill Livingstone, 2010:2835-60.
   Google Scholar
• CiofuO, HansenCR, HøibyN. Respiratory bacterial infections in cystic fibrosis. Curr Opin Pulm Med2013; 19:251 - 8; http://dx.doi.org/10.1097/MCP.0b013e32835f1afc; PMID: 23449384
   PubMed Web of Science ®Google Scholar
• McShanePJ, NaureckasET, TinoG, StrekME. Non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med2013; 188:647 - 56; PMID: 23898922
   PubMed Web of Science ®Google Scholar
• DesaiH, EschbergerK, WronaC, GroveL, AgrawalA, GrantB, YinJ, ParameswaranGI, MurphyT, SethiS. Bacterial colonization increases daily symptoms in patients with chronic obstructive pulmonary disease. Ann Am Thorac Soc2014; 11:303 - 9; http://dx.doi.org/10.1513/AnnalsATS.201310-350OC; PMID: 24423399
   PubMedGoogle Scholar
• GellatlySL, HancockRE. Pseudomonas aeruginosa: new insights into pathogenesis and host defenses. Pathog Dis2013; 67:159 - 73; http://dx.doi.org/10.1111/2049-632X.12033; PMID: 23620179
   PubMed Web of Science ®Google Scholar
• CrabbéA, LedesmaMA, NickersonCA. Mimicking the host and its microenvironment in vitro for studying mucosal infections by Pseudomonas aeruginosa. Pathog Dis2014; 71:1 - 19; http://dx.doi.org/10.1111/2049-632X.12180; PMID: 24737619
   PubMed Web of Science ®Google Scholar
• SievertDM, RicksP, EdwardsJR, SchneiderA, PatelJ, SrinivasanA, KallenA, LimbagoB, FridkinS, National Healthcare Safety Network (NHSN) Team and Participating NHSN Facilities. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol2013; 34:1 - 14; http://dx.doi.org/10.1086/668770; PMID: 23221186
   PubMed Web of Science ®Google Scholar
• VincentJL, RelloJ, MarshallJ, SilvaE, AnzuetoA, MartinCD, MorenoR, LipmanJ, GomersallC, SakrY, et al, EPIC II Group of Investigators. International study of the prevalence and outcomes of infection in intensive care units. JAMA2009; 302:2323 - 9; http://dx.doi.org/10.1001/jama.2009.1754; PMID: 19952319
   PubMed Web of Science ®Google Scholar
• SunHY, FujitaniS, QuintilianiR, YuVL. Pneumonia due to Pseudomonas aeruginosa: part II: antimicrobial resistance, pharmacodynamic concepts, and antibiotic therapy. Chest2011; 139:1172 - 85; http://dx.doi.org/10.1378/chest.10-0167; PMID: 21540216
   PubMed Web of Science ®Google Scholar
• StaudingerBJ, MullerJF, HalldórssonS, BolesB, AngermeyerA, NguyenD, RosenH, BaldurssonO, GottfreðssonM, GuðmundssonGH, et al. Conditions associated with the cystic fibrosis defect promote chronic Pseudomonas aeruginosa infection. Am J Respir Crit Care Med2014; 189:812 - 24; http://dx.doi.org/10.1164/rccm.201312-2142OC; PMID: 24467627
   PubMed Web of Science ®Google Scholar
• RelloJ, RuéM, JubertP, MusesG, SoñoraR, VallésJ, NiedermanMS. Survival in patients with nosocomial pneumonia: impact of the severity of illness and the etiologic agent. Crit Care Med1997; 25:1862 - 7; http://dx.doi.org/10.1097/00003246-199711000-00026; PMID: 9366771
   PubMed Web of Science ®Google Scholar
• ParkinsMD, GregsonDB, PitoutJD, RossT, LauplandKB. Population-based study of the epidemiology and the risk factors for Pseudomonas aeruginosa bloodstream infection. Infection2010; 38:25 - 32; http://dx.doi.org/10.1007/s15010-009-9145-9; PMID: 20012908
   PubMed Web of Science ®Google Scholar
• SandersDB, LiZ, LaxovaA, RockMJ, LevyH, CollinsJ, FerecC, FarrellPM. Risk factors for the progression of cystic fibrosis lung disease throughout childhood. Ann Am Thorac Soc2014; 11:63 - 72; http://dx.doi.org/10.1513/AnnalsATS.201309-303OC; PMID: 24261460
   PubMedGoogle Scholar
• KeremE, VivianiL, ZolinA, MacNeillS, HatziagorouE, EllemunterH, DrevinekP, GulmansV, KrivecU, OlesenH, ECFS Patient Registry Steering Group. Factors associated with FEV1 decline in cystic fibrosis: analysis of the ECFS Patient Registry. Eur Respir J2014; 43:125 - 33; http://dx.doi.org/10.1183/09031936.00166412; PMID: 23598952
   PubMed Web of Science ®Google Scholar
• LoebingerMR, WellsAU, HansellDM, ChinyanganyaN, DevarajA, MeisterM, WilsonR. Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. Eur Respir J2009; 34:843 - 9; http://dx.doi.org/10.1183/09031936.00003709; PMID: 19357155
   PubMed Web of Science ®Google Scholar
• AlmagroP, SalvadóM, Garcia-VidalC, Rodríguez-CarballeiraM, CuchiE, TorresJ, HerediaJL. Pseudomonas aeruginosa and mortality after hospital admission for chronic obstructive pulmonary disease. Respiration2012; 84:36 - 43; http://dx.doi.org/10.1159/000331224; PMID: 21996555
   PubMed Web of Science ®Google Scholar
• FerkolT, SchraufnagelD. The global burden of respiratory disease. Ann Am Thorac Soc2014; 11:404 - 6; http://dx.doi.org/10.1513/AnnalsATS.201311-405PS; PMID: 24673696
   PubMedGoogle Scholar
• WilliamsBJ, DehnbostelJ, BlackwellTS. Pseudomonas aeruginosa: host defence in lung diseases. Respirology2010; 15:1037 - 56; http://dx.doi.org/10.1111/j.1440-1843.2010.01819.x; PMID: 20723140
   PubMed Web of Science ®Google Scholar
• HøibyN. Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. BMC Med2011; 9:32; http://dx.doi.org/10.1186/1741-7015-9-32; PMID: 21463524
   PubMed Web of Science ®Google Scholar
• HurleyMN, CámaraM, SmythAR. Novel approaches to the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. Eur Respir J2012; 40:1014 - 23; http://dx.doi.org/10.1183/09031936.00042012; PMID: 22743672
   PubMed Web of Science ®Google Scholar
• VincentJL. Vaccine development and passive immunization for Pseudomonas aeruginosa in critically ill patients: a clinical update. Future Microbiol2014; 9:457 - 63; http://dx.doi.org/10.2217/fmb.14.10; PMID: 24810345
   PubMed Web of Science ®Google Scholar
• CohenTS, PrinceA. Cystic fibrosis: a mucosal immunodeficiency syndrome. Nat Med2012; 18:509 - 19; http://dx.doi.org/10.1038/nm.2715; PMID: 22481418
   PubMed Web of Science ®Google Scholar
• O’SullivanBP, FreedmanSD. Cystic fibrosis. Lancet2009; 373:1891 - 904; http://dx.doi.org/10.1016/S0140-6736(09)60327-5; PMID: 19403164
   PubMed Web of Science ®Google Scholar
• HartlD, GaggarA, BrusciaE, HectorA, MarcosV, JungA, GreeneC, McElvaneyG, MallM, DöringG. Innate immunity in cystic fibrosis lung disease. J Cyst Fibros2012; 11:363 - 82; http://dx.doi.org/10.1016/j.jcf.2012.07.003; PMID: 22917571
   PubMed Web of Science ®Google Scholar
• LavoieEG, WangdiT, KazmierczakBI. Innate immune responses to Pseudomonas aeruginosa infection. Microbes Infect2011; 13:1133 - 45; http://dx.doi.org/10.1016/j.micinf.2011.07.011; PMID: 21839853
   PubMed Web of Science ®Google Scholar
• YangL, JelsbakL, MolinS. Microbial ecology and adaptation in cystic fibrosis airways. Environ Microbiol2011; 13:1682 - 9; http://dx.doi.org/10.1111/j.1462-2920.2011.02459.x; PMID: 21429065
   PubMed Web of Science ®Google Scholar
• FolkessonA, JelsbakL, YangL, JohansenHK, CiofuO, HøibyN, MolinS. Adaptation of Pseudomonas aeruginosa to the cystic fibrosis airway: an evolutionary perspective. Nat Rev Microbiol2012; 10:841 - 51; http://dx.doi.org/10.1038/nrmicro2907; PMID: 23147702
   PubMed Web of Science ®Google Scholar
• Mayer-HamblettN, RosenfeldM, GibsonRL, RamseyBW, KulasekaraHD, Retsch-BogartGZ, MorganW, WolterDJ, PopeCE, HoustonLS, et al. Pseudomonas aeruginosa in vitro phenotypes distinguish cystic fibrosis infection stages and outcomes. Am J Respir Crit Care Med2014; 190:289 - 97; PMID: 24937177
   PubMed Web of Science ®Google Scholar
• DöringG, PierGB. Vaccines and immunotherapy against Pseudomonas aeruginosa. Vaccine2008; 26:1011 - 24; http://dx.doi.org/10.1016/j.vaccine.2007.12.007; PMID: 18242792
   PubMed Web of Science ®Google Scholar
• Sedlak-WeinsteinE, CrippsAW, KydJM, FoxwellAR. Pseudomonas aeruginosa: the potential to immunise against infection. Expert Opin Biol Ther2005; 5:967 - 82; http://dx.doi.org/10.1517/14712598.5.7.967; PMID: 16018741
   PubMed Web of Science ®Google Scholar
• ThomasLD, KydJM, BastinDA, DunkleyML, CrippsAW. Immunisation with non-integral OMPs promotes pulmonary clearance of Pseudomonas aeruginosa. FEMS Immunol Med Microbiol2003; 37:155 - 60; http://dx.doi.org/10.1016/S0928-8244(03)00073-7; PMID: 12832119
   PubMed Web of Science ®Google Scholar
• WuW, HuangJ, DuanB, TraficanteDC, HongH, RisechM, LoryS, PriebeGP. Th17-stimulating protein vaccines confer protection against Pseudomonas aeruginosa pneumonia. Am J Respir Crit Care Med2012; 186:420 - 7; http://dx.doi.org/10.1164/rccm.201202-0182OC; PMID: 22723292
   PubMed Web of Science ®Google Scholar
• PriebeGP, GoldbergJB. Vaccines for Pseudomonas aeruginosa: a long and winding road. Expert Rev Vaccines2014; 13:507 - 19; http://dx.doi.org/10.1586/14760584.2014.890053; PMID: 24575895
   PubMed Web of Science ®Google Scholar
• ClancyRL, DunkleyM. Acute exacerbations in COPD and their control with oral immunization with non-typeable haemophilus influenzae. Front Immunol2011; 2:7; http://dx.doi.org/10.3389/fimmu.2011.00007; PMID: 22566798
   PubMed Web of Science ®Google Scholar
• CrippsAW, DunkleyML, ClancyRL. Mucosal and systemic immunizations with killed Pseudomonas aeruginosa protect against acute respiratory infection in rats. Infect Immun1994; 62:1427 - 36; PMID: 8132349
   PubMed Web of Science ®Google Scholar
• MacmillanH, NorimineJ, BraytonKA, PalmerGH, BrownWC. Physical linkage of naturally complexed bacterial outer membrane proteins enhances immunogenicity. Infect Immun2008; 76:1223 - 9; http://dx.doi.org/10.1128/IAI.01356-07; PMID: 18086812
   PubMed Web of Science ®Google Scholar
• LeeJ-S, HeoY-J, LeeJK, ChoY-H. KatA, the major catalase, is critical for osmoprotection and virulence in Pseudomonas aeruginosa PA14. Infect Immun2005; 73:4399 - 403; http://dx.doi.org/10.1128/IAI.73.7.4399-4403.2005; PMID: 15972537
   PubMed Web of Science ®Google Scholar
• ThomasLD, DunkleyML, MooreR, ReynoldsS, BastinDA, KydJM, CrippsAW. Catalase immunization from Pseudomonas aeruginosa enhances bacterial clearance in the rat lung. Vaccine2000; 19:348 - 57; http://dx.doi.org/10.1016/S0264-410X(00)00146-8; PMID: 10930690
   PubMed Web of Science ®Google Scholar
• ElkinsJG, HassettDJ, StewartPS, SchweizerHP, McDermottTR. Protective role of catalase in Pseudomonas aeruginosa biofilm resistance to hydrogen peroxide. Appl Environ Microbiol1999; 65:4594 - 600; PMID: 10508094
   PubMed Web of Science ®Google Scholar
• HassettDJ, MaJ-F, ElkinsJG, McDermottTR, OchsnerUA, WestSEH, HuangCT, FredericksJ, BurnettS, StewartPS, et al. Quorum sensing in Pseudomonas aeruginosa controls expression of catalase and superoxide dismutase genes and mediates biofilm susceptibility to hydrogen peroxide. Mol Microbiol1999; 34:1082 - 93; http://dx.doi.org/10.1046/j.1365-2958.1999.01672.x; PMID: 10594832
   PubMed Web of Science ®Google Scholar
• AndradeJ, KarmaliA, CarrondoMA, FrazãoC. Structure of amidase from Pseudomonas aeruginosa showing a trapped acyl transfer reaction intermediate state. J Biol Chem2007; 282:19598 - 605; http://dx.doi.org/10.1074/jbc.M701039200; PMID: 17442671
   PubMed Web of Science ®Google Scholar
• StressmannFA, RogersGB, MarshP, LilleyAK, DanielsTW, CarrollMP, HoffmanLR, JonesG, AllenCE, PatelN, et al. Does bacterial density in cystic fibrosis sputum increase prior to pulmonary exacerbation?. J Cyst Fibros2011; 10:357 - 65; http://dx.doi.org/10.1016/j.jcf.2011.05.002; PMID: 21664196
   PubMed Web of Science ®Google Scholar
• ReidDW, LathamR, LamontIL, CamaraM, RoddamLF. Molecular analysis of changes in Pseudomonas aeruginosa load during treatment of a pulmonary exacerbation in cystic fibrosis. J Cyst Fibros2013; 12:688 - 99; http://dx.doi.org/10.1016/j.jcf.2013.03.008; PMID: 23706827
   PubMed Web of Science ®Google Scholar
• DeschaghtP, SchelstraeteP, Van SimaeyL, VanderkerckenM, RamanA, MahieuL, Van DaeleS, De BaetsF, VaneechoutteM. Is the improvement of CF patients, hospitalized for pulmonary exacerbation, correlated to a decrease in bacterial load?. PLoS One2013; 8:e79010; http://dx.doi.org/10.1371/journal.pone.0079010; PMID: 24312174
   PubMed Web of Science ®Google Scholar
• TunneyMM, EinarssonGG, WeiL, DrainM, KlemER, CardwellC, EnnisM, BoucherRC, WolfgangMC, ElbornJS. Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation. Am J Respir Crit Care Med2013; 187:1118 - 26; http://dx.doi.org/10.1164/rccm.201210-1937OC; PMID: 23348972
   PubMed Web of Science ®Google Scholar
• QuonBS, GossCH, RamseyBW. Inhaled antibiotics for lower airway infections. Ann Am Thorac Soc2014; 11:425 - 34; http://dx.doi.org/10.1513/AnnalsATS.201311-395FR; PMID: 24673698
   PubMedGoogle Scholar
• ChalmersJD, SmithMP, McHughBJ, DohertyC, GovanJR, HillAT. Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med2012; 186:657 - 65; http://dx.doi.org/10.1164/rccm.201203-0487OC; PMID: 22744718
   PubMed Web of Science ®Google Scholar
• DrenkardE, AusubelFM. Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation. Nature2002; 416:740 - 3; http://dx.doi.org/10.1038/416740a; PMID: 11961556
   PubMed Web of Science ®Google Scholar
• KydJM, McGrathJ, KrishnamurthyA. Mechanisms of bacterial resistance to antibiotics in infections of COPD patients. Curr Drug Targets2011; 12:521 - 30; http://dx.doi.org/10.2174/138945011794751519; PMID: 21194403
   PubMed Web of Science ®Google Scholar
• SchusterM, GreenbergEP. A network of networks: quorum-sensing gene regulation in Pseudomonas aeruginosa. Int J Med Microbiol2006; 296:73 - 81; http://dx.doi.org/10.1016/j.ijmm.2006.01.036; PMID: 16476569
   PubMed Web of Science ®Google Scholar
• PearsonJP, FeldmanM, IglewskiBH, PrinceA. Pseudomonas aeruginosa cell-to-cell signaling is required for virulence in a model of acute pulmonary infection. Infect Immun2000; 68:4331 - 4; http://dx.doi.org/10.1128/IAI.68.7.4331-4334.2000; PMID: 10858254
   PubMed Web of Science ®Google Scholar
• RumbaughKP, GriswoldJA, IglewskiBH, HamoodAN. Contribution of quorum sensing to the virulence of Pseudomonas aeruginosa in burn wound infections. Infect Immun1999; 67:5854 - 62; PMID: 10531240
   PubMed Web of Science ®Google Scholar
• LazenbyJJ, GriffinPE, KydJ, WhitchurchCB, CooleyMA. A quadruple knockout of lasIR and rhlIR of Pseudomonas aeruginosa PAO1 that retains wild-type twitching motility has equivalent infectivity and persistence to PAO1 in a mouse model of lung infection. PLoS One2013; 8:e60973; http://dx.doi.org/10.1371/journal.pone.0060973; PMID: 23593362
   PubMed Web of Science ®Google Scholar
• RasmussenTB, GivskovM. Quorum-sensing inhibitors as anti-pathogenic drugs. Int J Med Microbiol2006; 296:149 - 61; http://dx.doi.org/10.1016/j.ijmm.2006.02.005; PMID: 16503194
   PubMed Web of Science ®Google Scholar
• KaufmannGF, SartorioR, LeeSH, MeeJM, AltobellLJ3rd, KujawaDP, JeffriesE, ClaphamB, MeijlerMM, JandaKD. Antibody interference with N-acyl homoserine lactone-mediated bacterial quorum sensing. J Am Chem Soc2006; 128:2802 - 3; http://dx.doi.org/10.1021/ja0578698; PMID: 16506750
   PubMed Web of Science ®Google Scholar
• MiyairiS, TatedaK, FuseET, UedaC, SaitoH, TakabatakeT, IshiiY, HorikawaM, IshiguroM, StandifordTJ, et al. Immunization with 3-oxododecanoyl-L-homoserine lactone-protein conjugate protects mice from lethal Pseudomonas aeruginosa lung infection. J Med Microbiol2006; 55:1381 - 7; http://dx.doi.org/10.1099/jmm.0.46658-0; PMID: 17005787
   PubMed Web of Science ®Google Scholar
• CrippsAW, PeekK, DunkleyM, VentoK, MarjasonJK, McIntyreME, SizerP, CroftD, Sedlak-WeinsteinL. Safety and immunogenicity of an oral inactivated whole-cell pseudomonas aeruginosa vaccine administered to healthy human subjects. Infect Immun2006; 74:968 - 74; http://dx.doi.org/10.1128/IAI.74.2.968-974.2006; PMID: 16428742
   PubMed Web of Science ®Google Scholar
• Clancy R, Pang G, Dunkley M, Cripps A. Control of bacterial colonisation of the respiratory tract mucosa in man. In: Alan J Husband, Kenneth W Beagley, Robert L Clancy, Andrew M Collins, Allan W Cripps, Emery DL, eds. Mucosal Solutions: Advances in mucosal immunology. Sydney, Australia: University of Sydney, 1997:261-8.
   Google Scholar